Dendreon falls as analyst says J&J and Medivation prostate cancer drugs will surpass Provenge - Minneapolis Star Tribune

NEW YORK - Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors. THE SPARK: Analyst Biren Amin started covering Dendreon shares with an ...

Provenge And NeuVax: A Tale Of 2 Marvels - Seekingalpha.com

With each era of discovery it seems there is always a leader with the innovative foresight and fortitude to lead a revolution and conquer a foe. The tools used to defeat the enemy are considered to be marvels and are viewed as such by outsiders willing to ...

Dendreon falls as analyst starts coverage - Yahoo Finance

NEW YORK (AP) -- Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors. THE SPARK: Analyst Biren Amin started covering Dendreon ...

A Dendreon Options Trade: Hedging ASCO 2012 Data Releases - Seekingalpha.com

It seems that not a day goes by without a fierce debate over Provenge, its efficacy, and its future place in the prostate cancer market. Over the past year, Dendreon has suffered mightily, with the stock falling almost 82% as Provenge forecasts were cut ...

Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting - Marketwatch

SEATTLE, May 16, 2012 (BUSINESS WIRE) -- May 16, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE(R) (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking ...

Dendreon: SEC Opens Probe, Possibly Tied To Provenge Disclosures - Wall Street Journal

Dendreon Corp. (DNDN) said the U.S. Securities and Exchange Commission has begun a formal investigation, which may be related to shareholder lawsuits alleging the company misled investors about prostate-cancer drug Provenge. Dendreon said in its ...

Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting - Yahoo Finance

May 21, 2012–Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 – 23, 2012 in Atlanta ...

Dendreon: Analyst Sees “Epic” Price, Competition Challenges - Barron's Online

Dendreon makes Provenge, a prostate cancer treatment, but is facing competition from Johnson & Johnson’s (JNJ) drug Zytiga, as well as drug candidate MDV 3100 made by Medivation and Astellas Pharma. Against those two drugs, “we believe ...

Dendreon’s Provenge Works Best for Patients With Low PSA, Scientists Say - Xconomy

From the moment Dendreon started in business 20 years ago, most scientists have said that if its immune-booster for prostate cancer was going to work, it would probably work best at an early stage of disease, before tumors had gotten too ...

Can Dendreon Turn It On? - Barron's Online

The biotech's stock, down almost 80% since last year, plunged Tuesday after the maker of Provenge announced another quarterly loss. Dendreon has suffered a major relapse. Shares of Dendreon (ticker: DNDN), which is focused on cancer treatments ...